In the present study, we aimed to determine the time-course of neurochemical changes occurring following metabolic impairments produced by 3-nitropropionic (3NP) acid in a rat model of Huntington's disease. We found that the occurrence of striatal lesions was accompanied by (1) strong transcriptional alterations within the degenerative lateral striatum, (2) receptor upregulations within the preserved medial striatum, and (3) transcriptional increases within the unaltered cerebral cortex. These phenomena were preceded by transcriptional modifications in striatal subareas prone to degeneration even before the lesion was visible but not in the overlying cortex, known to be spared in this model. Of great interest, the density of A 2A receptor binding sites, located on striato-pallidal neurons, was (1) downregulated at the time of worsening of symptoms and (2) strongly upregulated within the spared medial striatum after the lesion occurrence. This study therefore highlights the differential neurochemical responses produced by 3NP depending on the fate of the metabolically inhibited area and strongly suggests the involvement of A 2A receptors in the development of striatal pathology under metabolic compromise. © 2002 Elsevier Science (USA)
INTRODUCTION
Huntington's disease (HD) 3 is an autosomal dominant neurodegenerative disorder characterized by both motor and cognitive symptoms (for review see Brouillet et al., 1999) . However, at present there are no therapeutical tools available for delaying the onset of the symptoms and the associated neurodegeneration, despite recent promising advances in the field of cell therapies (for review see Beal and Hantraye, 2001) .
HD is caused by an abnormal polyglutamine expansion in the huntingtin protein encoded by the IT15 gene (Huntington's Disease Collaborative Group, 1993) , leading to the formation of neuronal intranuclear inclusions (DiFiglia et al., 1997) and, for unclear reasons, to a preferential loss of the striatal GABAergic projecting medium-sized spiny neurons (Sieradzan and Mann, 2001; Vonsattel et al., 1985) . Among these, striato-pallidal cells have been suggested to be more vulnerable to the degenerative process (Glass et al., 2000; Reiner et al., 1988; Richfield et al., 1995; Sapp et al., 1995) . The molecular mechanisms by which polyglutamine expansion leads to specific striatal cell death are largely unknown. Alterations in gene tran-1 To whom correspondence and reprint requests should be addressed. Fax: ϩ32 2 555 41 21. E-mail: David.Blum@ulb.ac.be.
2 These authors contributed equally to this work. 3 Abbreviations used: 3NP, 3-nitropropionic acid; A 2A , Adenosine A 2A receptor; CO, cytochrome oxidase; D1, dopamine D1 receptor; D2, dopamine D2 receptor; DMSO, dimethylsulfoxide; Enk, Enkephalin; GAD, Glutamic acid decarboxylase; HD, Huntington's disease; NMDAR, N-methyl-d-aspartate receptor; NR1, NMDA receptor NR1 subunit; NR2A, NMDA receptor 2A subunit; NR2B, NMDA receptor 2B subunit; OD, optical density; PBS, phosphatebuffered saline; ROI, region of interest; SDH, succinate dehydrogenase; SSC, saline sodium citrate buffer; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. 
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